AU2001244509A1 - Method of treatment of conditions involving obstruction of blood flow - Google Patents

Method of treatment of conditions involving obstruction of blood flow

Info

Publication number
AU2001244509A1
AU2001244509A1 AU2001244509A AU4450901A AU2001244509A1 AU 2001244509 A1 AU2001244509 A1 AU 2001244509A1 AU 2001244509 A AU2001244509 A AU 2001244509A AU 4450901 A AU4450901 A AU 4450901A AU 2001244509 A1 AU2001244509 A1 AU 2001244509A1
Authority
AU
Australia
Prior art keywords
treatment
blood flow
conditions involving
obstruction
involving obstruction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001244509A
Inventor
Eli Keshet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of AU2001244509A1 publication Critical patent/AU2001244509A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001244509A 2000-03-30 2001-03-28 Method of treatment of conditions involving obstruction of blood flow Abandoned AU2001244509A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19326900P 2000-03-30 2000-03-30
US60193269 2000-03-30
PCT/IL2001/000289 WO2001072339A2 (en) 2000-03-30 2001-03-28 Method of treatment of conditions involving obstruction of blood flow

Publications (1)

Publication Number Publication Date
AU2001244509A1 true AU2001244509A1 (en) 2001-10-08

Family

ID=22712920

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001244509A Abandoned AU2001244509A1 (en) 2000-03-30 2001-03-28 Method of treatment of conditions involving obstruction of blood flow

Country Status (2)

Country Link
AU (1) AU2001244509A1 (en)
WO (1) WO2001072339A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348001B2 (en) 2003-08-12 2008-03-25 Dyax Corp. Tie1-binding ligands
US7485297B2 (en) 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
US7871610B2 (en) 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955291A (en) * 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
DE69534180T2 (en) * 1994-09-22 2006-03-02 Licentia Ltd. PROMOTER OF TIE RECEPTOR PROTEIN KINASE
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues

Also Published As

Publication number Publication date
WO2001072339A2 (en) 2001-10-04
WO2001072339A3 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
AU2002326600A1 (en) Side-exit catheter and method for its use
AU2002257936A1 (en) Methods of well treatment
AU2002215261A1 (en) Method and arrangement for treatment of fluid
AU2002350088A1 (en) Compositions and methods for reducing blood and fluid loss from open wounds
AU2002332430A1 (en) Methods of treating neuropilin-mediated diseases
AU2002359738A1 (en) Method of sterilizing heart valves
AU2003278361A1 (en) Method of water treatment
AU2002366338A1 (en) Catheter having improved curve retention and method of manufacture
IL160835A0 (en) Catheter and method of using same
AU2001286983A1 (en) Method of treatment
AU2001240046A1 (en) Method of treating skin conditions
AU2002220257A1 (en) Methods of treatment involving human mda-7
AU2002230748A1 (en) Method and catheter for aerating fluids for medical uses
AU2001244509A1 (en) Method of treatment of conditions involving obstruction of blood flow
AU2001244461A1 (en) Venous line catheter and method of operating the same
AU2001262177A1 (en) Method of treatment
AUPR536401A0 (en) Method for treatment of waste water
AUPR731901A0 (en) Method of treatment
AU2002249891A1 (en) Compounds and methods for the diagnosis and treatment of babesia infection
AU4594600A (en) Determination of blood flow parameters
AU2002322862A1 (en) Methods and compositions for diagnosis and treatment of vascular conditions
AU2001253560A1 (en) Methods of treatment
AU2003274359A1 (en) Treatment of fluids
AU2002346654A1 (en) Dialysis catheter set and method of using same
AU2001288416A1 (en) Methods and systems for facilitating the diagnosis and treatment of schizophrenia